Third, proliferative and oncogenic activities are attributed to GILZ for ovarian cancer and melanoma and resistance to cyclopamine therapy in lung cancer is attributed to high GILZ expression (21–23). This evidence concerns the gene TSC22D3 and lung carcinoma.